Samsung Bioepis Gains Japan Approval for Ustekinumab Biosimilar
Incheon, South Korea, September 3, 2026 Samsung Bioepis has announced that its ustekinumab biosimilar has received marketing approval in...
IL-12
Advertisement
Gilead Wins FDA Approval for Bixlenvo HIV Single Tablet
FOSTER CITY, Calif. – August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Adicet Bio Gains FDA Clearance for ADI-212 IND in mCRPC
REDWOOD CITY, Calif. – August 27, 2026 Adicet Bio, Inc. announced that the U.S. Food and Drug Administration (FDA)...
RedHill Advances Opaganib for Emerging Ebola Outbreak
Tel Aviv, Israel & Raleigh, N.C., July 28, 2026 RedHill Biopharma Ltd. has announced significant progress in the emergency...
Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
Advertisements
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
A2 Bio Reports First CAR-T Complete Response in Lung Cancer
CHICAGO, Illinois, 21 May 2026 A2 Biotherapeutics, Inc. announced new safety and efficacy results from its ongoing EVEREST-2 Phase...
Samsung Bioepis Launches First Japan Biosimilar
INCHEON, South Korea, May 20, 2026 Samsung Bioepis has announced the official launch of Ustekinumab BS 45 mg Syringe...
PDS Biotech Reports Breakthrough Phase 2 mCRC Results
Princeton, New Jersey, U.S. | April 15, 2026 PDS Biotechnology has announced the publication of positive interim Phase 2...
Advertisement
